DemeRx Gains FDA IND Clearance for DMX-1001 in AUD

Miami, Florida, USA – April 23, 2026

DemeRx announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for DMX-1001 (oral noribogaine), marking a critical milestone in advancing a novel neuroplastogen therapy for alcohol use disorder (AUD). The acceptance provides a “safe to proceed” authorization, enabling the company to progress toward Phase 2 clinical trials, with initiation planned in 2027. This development highlights growing momentum in next-generation addiction therapeutics focused on disease modification and neural repair.

FDA IND Acceptance Validates Novel Neuroplastogen Approach

The FDA’s IND acceptance for DMX-1001 underscores the therapeutic potential of neuroplastogens, a new class of treatments designed to restore neural pathways disrupted by chronic substance abuse. DMX-1001 is based on oral noribogaine, a long-acting metabolite that remains active in the body for extended periods, promoting sustained neuroplastic changes and functional recovery of brain circuits.

This mechanism represents a paradigm shift from traditional addiction therapies, which primarily focus on symptom management rather than addressing underlying neurological damage. By combining neuroplasticity with polypharmacology, DMX-1001 aims to deliver comprehensive therapeutic effects, including reduction of cravings, improvement in mood, and long-term relapse prevention.

The IND clearance follows a successful multiple ascending dose (MAD) clinical study in healthy volunteers, which demonstrated favorable safety, tolerability, and pharmacokinetic profiles, supporting advancement into patient-focused trials.

Addressing a Major Public Health Challenge in Alcohol Use Disorder

Alcohol use disorder remains a significant global health concern, affecting more than 29 million individuals in the United States alone and contributing to high rates of morbidity, mortality, and healthcare burden. Despite available treatments, less than 5% of patients receive medication, and approximately 60% relapse within six months, highlighting the urgent need for innovative and effective therapies.

DMX-1001 is designed to address these challenges by targeting both addiction-related neural dysfunction and associated mental health conditions, such as depression and anxiety, which are major contributors to relapse. The therapy’s rapid antidepressant and anxiolytic effects further enhance its potential to improve treatment outcomes and patient adherence.

By focusing on disease modification rather than short-term symptom control, DMX-1001 could significantly reduce relapse rates and improve long-term recovery outcomes, offering a transformative solution for patients with AUD.

Pathway to Phase 2 and Future Clinical Impact

With IND acceptance secured, DemeRx plans to conduct an alcohol interaction study, a key step required before initiating Phase 2 clinical trials in patients with AUD. The company expects to begin Phase 2 development in 2027, advancing DMX-1001 toward potential regulatory approval and commercialization.

This milestone reflects broader trends in the pharmaceutical industry toward innovative CNS therapeutics and precision neuropsychiatric medicine, where therapies are designed to target underlying disease biology with improved efficacy and durability.

As addiction continues to be recognized as a chronic neurological disorder, the development of therapies like DMX-1001 signals a shift toward holistic, mechanism-driven treatment approaches. If successful, DMX-1001 could become a first-in-class therapy that redefines the standard of care for alcohol use disorder, addressing both biological and psychological dimensions of addiction.

Source: DemeRx press release